Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alan Baribeau

Ophthalmology San Antonio, TX Medical Doctor

NPI 1952301384 CMS profile 223752

7830 Louis Pasteur, San Antonio, TX 78229

Open in the dashboard

General payments

$11,237

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alan Baribeau of San Antonio, TX is reported in the CMS Open Payments database as having received $11,237 across 234 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,559 32
2024 General $1,661 38
2023 General $1,583 34
2022 General $1,056 23
2021 General $780 28
2020 General $856 33
2019 General $3,740 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Baribeau
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Alan Baribeau were reported at $1,559. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Alan Baribeau Ophthalmology median Middle half National median
2019 $3,740 $258 $104–$655 $163
2020 $856 $126 $45–$321 $114
2021 $780 $205 $76–$534 $132
2022 $1,056 $266 $100–$678 $149
2023 $1,583 $308 $117–$745 $160
2024 $1,661 $340 $127–$846 $164
2025 $1,559 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Surgical Vision, Inc. $2,422 16 payments
  2. AbbVie, Inc. $1,597 41 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $914 36 payments
  4. TissueTech, Inc. $829 14 payments
  5. Bausch & Lomb Americas Inc. $730 26 payments
  6. Allergan Inc. $647 20 payments
  7. Alcon Vision LLC $546 8 payments
  8. Novartis Pharmaceuticals Corporation $490 10 payments
  9. Dompe US, Inc. $362 9 payments
  10. Astellas Pharma US Inc $305 5 payments
  11. Other $2,393 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,592 228 payments
  2. Travel and Lodging $1,399 1 payment
  3. Education $146 4 payments
  4. Entertainment $99 1 payment
Products named General payments · program years 2019–2025
  1. Tecnis Symphony IOL $1,719 2 payments
  2. Tecnis Symphony Toric IOL $1,719 2 payments
  3. Tecnis 3-piece IOL $1,719 2 payments
  4. Tecnis 1-piece IOL $1,719 2 payments
  5. DURYSTA $1,377 36 payments
  6. VYZULTA $744 33 payments
  7. MIEBO $408 12 payments
  8. OXERVATE $362 9 payments
  9. BESIVANCE $337 17 payments
  10. XIIDRA $321 13 payments
  11. Other $8,179 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

4,853

Median for Ophthalmology: 891

Drug cost

$462,760

Median for Ophthalmology: $68,233

Branded share of claims

56.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyzulta Latanoprostene Bunod Brand 139 $53,763
Rocklatan Netarsudil Mesylat/Latanoprost Brand 94 $51,790
Brinzolamide Generic 216 $49,307
Restasis Cyclosporine Brand 44 $42,687
Lumigan Bimatoprost Brand 46 $27,805
Xiidra Lifitegrast Brand 18 $26,350
Alphagan P Brimonidine Tartrate Brand 50 $24,053
Zylet Tobramycin/Lotepred Etab Brand 32 $19,919
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 993 $19,828
Dorzolamide-Timolol Dorzolamide/Timolol/Pf Brand 93 $19,257

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$235,277

Of which drugs: $60,066

Medicare patients

512

Average age 75

Services billed

3,455

309 women, 203 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Arthritis 39%
Chronic kidney disease 31%
Ischemic heart disease 30%
Depression 20%
Heart failure 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $357
$357 — —
OXERVATE
  • Dompe US, Inc. $157
$157 — —
Rocklatan
  • Alcon Vision LLC $151
$151 94 —
Izervay
  • Astellas Pharma US Inc $127
$127 — —
TEPEZZA
  • Amgen Inc. $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record